Evidence map›Paper›PMID 42101515›Full record

ReviewMolecular biology reports2026

Research progress on the roles and mechanisms of flavonoid monomers in liver diseases: a review.

Weijia Zhang, Mi Chen, Chenxia Lu, Li Li, Shupeng Dai, Shengnan Zhang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Weijia Zhang *Hubei Key Laboratory of Diabetes and Angiopathy, School of Pharmacy, Hubei University of Science and Technology, Xianning, 437100, PR China.
Mi Chen *Hubei Key Laboratory of Diabetes and Angiopathy, School of Pharmacy, Hubei University of Science and Technology, Xianning, 437100, PR China.
Chenxia Lu *Institute of Liver Diseases, Hubei Key Laboratory of the theory and application research of liver and kidney in traditional Chinese medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430061, China.
Li LiHubei Key Laboratory of Diabetes and Angiopathy, School of Pharmacy, Hubei University of Science and Technology, Xianning, 437100, PR China.
Shupeng DaiHubei Key Laboratory of Diabetes and Angiopathy, School of Pharmacy, Hubei University of Science and Technology, Xianning, 437100, PR China.
Shengnan ZhangHubei Key Laboratory of Diabetes and Angiopathy, School of Pharmacy, Hubei University of Science and Technology, Xianning, 437100, PR China. zsn0106@hbust.edu.cn.

Funding

Foundation of Hubei University of Science and Technology BK202336Foundation of Hubei University of Science and Technology BK202440Funded by China Postdoctoral Science Foundation 2025M784010Natural Science Foundation of Hubei Province 2024AFB494Scientific Research Project of Hubei Provincial Department of Education Q20242807
6 · The paper itself

Abstract

The liver, a vital metabolic organ with critical roles in detoxification, digestion, and metabolism, is highly susceptible to damage caused by the consumption of alcohol and drugs or infection of viruses. Persistent injury to the liver may progress to severe conditions. Flavonoid monomers, characterized by a fundamental 2-phenylchromone backbone, are a class of traditional Chinese medicine-derived natural polyphenolic compounds. These compounds can inhibit inflammation, oxidation, fibrosis, cancer, and diverse other pathological disorders pharmacologically, which are promising for the treatment of liver diseases. However, the specific mechanisms of flavonoid monomers in liver diseases remain unclear. Based on an extensive literature review, this work summarizes recent research advances on the mechanism of flavonoid monomers in liver diseases. This review is expected to provide novel insights that support the therapeutic application of flavonoid monomers in liver disease treatment.

Indexed as

FlavonoidsLiver DiseasesAnimalsHumansLiverMedicine, Chinese TraditionalFlavonoidsFatty liverFlavonoid monomersHepatic fibrosisHepatocellular carcinomaLiver injury

Identifiers

PMID42101515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.